https://m2.mtmt.hu/ hun 2026-05-02 10:02 JournalArticle 35780405 VALIDATED true 0 false 2025-03-20T05:53:58.776+0000 2025-03-20T05:52:55.182+0000 2025-02-23T15:40:07.397+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 2025-03-20T05:52:54.203+0000 2025-03-20T05:52:54.370+0000 true 521 Szuper Admin /api/admin/521 Admin Szuper Admin (admin) true false false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Liu, J. true true /api/journal/686 REVIEWED BIOCHEMICAL PHARMACOLOGY 0006-2952 1873-2968 true false 686 false 686 true 0006-2952 1873-2968 Journal FOREIGN 233 116789 116789 15 2025 Brain tumors create special difficulties because of their position and the protective covering of blood brain barrier (BBB) that restricts efficient medication access. Treatment alternatives such as surgery and chemotherapy demonstrate poor performance against severe brain tumors. The use of immune checkpoint inhibitors (ICIs) hints at effective cancer therapy; however, their application to brain cancer faces challenges due to inefficient delivery through the BBB and the tumor's suppressive environment. Nanoengineering can increase the transport of ICIs to brain tumors. Numerous nano-delivery systems such as liposomes and micelles have explored ways to avoid the BBB via transcytosis and the EPR mechanism. Functionalization of nanocarriers enhances targeting tumor cells and improves treatment accuracy. New developments involve delivering ICIs together with adjuvants to change the TME and focusing on immune cells such as TAMs and Tregs to boost immunity against tumors. Nanoengineered ICIs have shown effective improvement in animal models by reducing toxicity and enhancing efficacy. Converting these successes into real clinical trials is not easy as they face regulatory concerns and safety challenges. Clinical trials currently examine the use of nanocarriers for treating brain cancer; however, scalability’ and ’long-term safety’ continue to pose challenges. Future approaches will focus on combining customized medicine with advanced nanotechnology and AI to refine treatment methods. Despite obstacles ahead, nanotechnology-based ICIs offer a hopeful approach to enhance brain cancer efficacy and address existing therapeutic constraints. © 2025 Elsevier Inc. 2025 true true true false false false NONE 2025-03-20 false 0 0 0 0 0 0 0 0 0 0 0 0 1 1 D1 false false false false 2025-05-24T14:41:15.965+0000 4 20 0 4 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 123472509 /api/authorship/123472509 Liu, J. 1 0.25 true false false Liu J. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123472510 /api/authorship/123472510 Wang, Y. 2 0.25 false false false Wang Y. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123472511 /api/authorship/123472511 Song, Z. 3 0.25 false false false Song Z. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 123472512 /api/authorship/123472512 Zhang, Y. 4 0.25 false true false Zhang Y. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 28456379 /api/publicationidentifier/28456379 DOI: 10.1016/j.bcp.2025.116789 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1016/j.bcp.2025.116789 https://doi.org/10.1016/j.bcp.2025.116789 false true PublicationIdentifier 29043216 /api/publicationidentifier/29043216 WoS: 001424517500001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001424517500001 https://www.webofscience.com/wos/woscc/full-record/001424517500001 false true PublicationIdentifier 28456378 /api/publicationidentifier/28456378 Scopus: 85216918520 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true 85216918520 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85216918520 false true SjrRating 11559914 /api/sjrrating/11559914 sjr:Q1 (2025) Scopus - Biochemistry BIOCHEMICAL PHARMACOLOGY 0006-2952 1873-2968 71 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1303 /api/classificationexternal/1303 Scopus - Biochemistry true 1303 true Q1 FROM_PREVIOUS_TO_LAST_YEAR true true Reference 63966841 /api/reference/63966841 1. 70(4):299-312 1 false true Reference 63966938 /api/reference/63966938 2. 85(4):897-908 2 false true Reference 63966976 /api/reference/63966976 3. with an extensive focus on TLR agonists and antagonists (2021) IUBMB Life, 73 (1), pp. 10-25 3 false true Reference 63966822 /api/reference/63966822 4. Perrin, S.L., Samuel, M.S., Koszyca, B., Brown, M.P., Ebert, L.M., Oksdath, M., Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments (2019) Biochem. Soc. Trans., 47 (2), pp. 625-638 4 false true Reference 63966823 /api/reference/63966823 5. Yalamarty, S.S.K., Filipczak, N., Li, X., Subhan, M.A., Parveen, F., Ataide, J.A., Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM) (2023) Cancers, 15 (7), p. 2116 5 false true Reference 63966824 /api/reference/63966824 6. Shiravand, Y., Khodadadi, F., Kashani, S.M.A., Hosseini-Fard, S.R., Hosseini, S., Sadeghirad, H., Immune checkpoint inhibitors in cancer therapy (2022) Curr. Oncol., 29 (5), pp. 3044-3060 6 false true Reference 63966825 /api/reference/63966825 7. Badani, A., Ozair, A., Khasraw, M., Woodworth, G.F., Tiwari, P., Ahluwalia, M.S., Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions (2024) J. Neurooncol, 1-17 7 false true Reference 63966826 /api/reference/63966826 8. Cremolini, C., Vitale, E., Rastaldo, R., Giachino, C., Advanced nanotechnology for enhancing immune checkpoint blockade therapy (2021) Nanomaterials, 11 (3), p. 661 8 false true Reference 63966827 /api/reference/63966827 9. Peng, X., Fang, J., Lou, C., Yang, L., Shan, S., Wang, Z., Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy (2024) Acta Pharm. Sin. B 9 false true Reference 63966828 /api/reference/63966828 10. Zhao, Y., Liu, X., Liu, X., Yu, J., Bai, X., Wu, X., Combination of phototherapy with immune checkpoint blockade: theory and practice in cancer (2022) Front. Immunol., 13 10 false true Reference 63966829 /api/reference/63966829 11. Jiang, K., Wang, Q., Chen, X.-L., Wang, X., Gu, X., Feng, S., Nanodelivery optimization of IDO1 inhibitors in tumor immunotherapy: challenges and strategies (2024) Int. J. Nanomed., 8847-82 11 false true Reference 63966830 /api/reference/63966830 12. Brem, S.S., Bierman, P.J., Brem, H., Butowski, N., Chamberlain, M.C., Chiocca, E.A., Central nervous system cancers (2011) J. Natl. Compr. Canc. Netw., 9 (4), pp. 352-400 12 false true Reference 63966831 /api/reference/63966831 13. Pichaivel, M., Anbumani, G., Theivendren, P., Gopal, M., An overview of brain tumor (2022) Brain Tumors., 1, pp. 1-10 13 false true Reference 63966832 /api/reference/63966832 14. Delgado-Martín, B., Medina, M.Á., Advances in the knowledge of the molecular biology of glioblastoma and its impact in patient diagnosis, stratification, and treatment (2020) Adv. Sci., 7 (9) 14 false true Reference 63966833 /api/reference/63966833 15. Aldape, K., Brindle, K.M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M.R., Challenges to curing primary brain tumours (2019) Nat. Rev. Clin. Oncol., 16 (8), pp. 509-520 15 false true Reference 63966834 /api/reference/63966834 16. Ilic, I., Ilic, M., International patterns and trends in the brain cancer incidence and mortality: an observational study based on the global burden of disease (2023) Heliyon., 9 (7) 16 false true Reference 63966835 /api/reference/63966835 17. Ohgaki, H., Kleihues, P., Epidemiology and etiology of gliomas (2005) Acta Neuropathol., 109, pp. 93-108 17 false true Reference 63966836 /api/reference/63966836 18. Cantrell, J.N., Waddle, M.R., Rotman, M., Peterson, J.L., Ruiz-Garcia, H., Heckman, M.G., (2019), editors. Progress toward long-term survivors of glioblastoma. Mayo Clinic proceedings Elsevier 18 false true Reference 63966837 /api/reference/63966837 19. Schiffer, D., Brain tumor pathology: current diagnostic hotspots and pitfalls (2006), Springer Science & Business Media 19 false true Reference 63966838 /api/reference/63966838 20. Nabors, L.B., Ammirati, M., Bierman, P.J., Brem, H., Butowski, N., Chamberlain, M.C., Central nervous system cancers (2013) J. Natl. Compr. Canc. Netw., 11 (9), pp. 1114-1151 20 false true Reference 63966839 /api/reference/63966839 21. Delgado-López, P., Corrales-García, E., Survival in glioblastoma: a review on the impact of treatment modalities (2016) Clin. Transl. Oncol., 18 (11), pp. 1062-1071 21 false true Reference 63966840 /api/reference/63966840 22. Tan, A.C., Ashley, D.M., López, G.Y., Malinzak, M., Friedman, H.S., Khasraw, M., Management of glioblastoma: State of the art and future directions. CA: a cancer journal for clinicians. 2020 22 false true Reference 63966842 /api/reference/63966842 23. Lara-Velazquez, M., Al-Kharboosh, R., Jeanneret, S., Vazquez-Ramos, C., Mahato, D., Tavanaiepour, D., Advances in brain tumor surgery for glioblastoma in adults (2017) Brain Sci., 7 (12), p. 166 23 false true Reference 63966843 /api/reference/63966843 24. Lee, Y.W., Cho, H.J., Lee, W.H., Sonntag, W.E., Whole brain radiation-induced cognitive impairment: pathophysiological mechanisms and therapeutic targets (2012) Biomol. Ther., 20 (4), p. 357 24 false true Reference 63966844 /api/reference/63966844 25. Franchino, F., Rudà, R., Soffietti, R., Mechanisms and therapy for cancer metastasis to the brain (2018) Front. Oncol., 8, p. 161 25 false true Reference 63966845 /api/reference/63966845 26. Koukourakis, G.V., Kouloulias, V., Zacharias, G., Papadimitriou, C., Pantelakos, P., Maravelis, G., Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy 26 false true Reference 63966846 /api/reference/63966846 27. a review article (2009) Molecules, 14 (4), pp. 1561-1577 27 false true Reference 63966847 /api/reference/63966847 28. Lee, C.Y., Strategies of temozolomide in future glioblastoma treatment (2017) OncoTargets Ther., pp. 265-270 28 false true Reference 63966848 /api/reference/63966848 29. Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M.D., Karpel-Massler, G., Temozolomide and other alkylating agents in glioblastoma therapy (2019) Biomedicines., 7 (3), p. 69 29 false true Reference 63966849 /api/reference/63966849 30. Fan, C., Liu, W., Cao, H., Wen, C., Chen, L., Jiang, G., O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell death & disease. 2013 30 false true Reference 63966850 /api/reference/63966850 31. 4(10):e876-e 31 false true Reference 63966851 /api/reference/63966851 32. Belkhodja, F., Targeted therapy to overcome the blood-brain barrier in treating Glioblastoma (2023) Hochschule Rhein-Waal 32 false true Reference 63966852 /api/reference/63966852 33. Lesniak, M.S., Brem, H., Targeted therapy for brain tumours (2004) Nat. Rev. Drug Discov., 3 (6), pp. 499-508 33 false true Reference 63966853 /api/reference/63966853 34. Régina, A., Demeule, M., Laplante, A., Jodoin, J., Dagenais, C., Berthelet, F., Multidrug resistance in brain tumors: roles of the blood–brain barrier (2001) Cancer Metastasis Rev., 20, pp. 13-25 34 false true Reference 63966854 /api/reference/63966854 35. Strickland, M.R., Alvarez-Breckenridge, C., Gainor, J.F., Brastianos, P.K., Tumor immune microenvironment of brain metastases: toward unlocking antitumor immunity (2022) Cancer Discov., 12 (5), pp. 1199-1216 35 false true Reference 63966855 /api/reference/63966855 36. Zhou, S., Xie, J., Huang, Z., Deng, L., Wu, L., Yu, J., Anti-PD-(L) 1 immunotherapy for brain metastases in non-small cell lung cancer: mechanisms, advances, and challenges (2021) Cancer Lett., 502, pp. 166-179 36 false true Reference 63966856 /api/reference/63966856 37. Yshii, L.M., Hohlfeld, R., Liblau, R.S., Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives (2017) Nat. Rev. Neurol., 13 (12), pp. 755-763 37 false true Reference 63966857 /api/reference/63966857 38. Liu, H.-J., Xu, P., Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor (2022) Adv. Drug Deliv. Rev., 191 38 false true Reference 63966858 /api/reference/63966858 39. Bhargav, A.G., Mondal, S.K., Garcia, C.A., Green, J.J., Quiñones-Hinojosa, A., Nanomedicine revisited: next generation therapies for brain cancer (2020) Advanced Therapeutics., 3 (10) 39 false true Reference 63966859 /api/reference/63966859 40. Sampson, J.H., Gunn, M.D., Fecci, P.E., Ashley, D.M., Brain immunology and immunotherapy in brain tumours (2020) Nat. Rev. Cancer, 20 (1), pp. 12-25 40 false true Reference 63966860 /api/reference/63966860 41. Nayyar, N., Preclinical development of precision immuno-oncology approaches for brain metastases (2023) Umass Chan Medical School 41 false true Reference 63966861 /api/reference/63966861 42. Grabowski, M.M., Sankey, E.W., Ryan, K.J., Chongsathidkiet, P., Lorrey, S.J., Wilkinson, D.S., Immune suppression in gliomas (2021) J. Neurooncol, 151, pp. 3-12 42 false true Reference 63966862 /api/reference/63966862 43. Waisman, A., Johann, L., Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity (2018) J. Mol. Med., 96 (12), pp. 1279-1292 43 false true Reference 63966863 /api/reference/63966863 44. Mapunda, J.A., Tibar, H., Regragui, W., Engelhardt, B., How does the immune system enter the brain? (2022) Front. Immunol., 13 44 false true Reference 63966864 /api/reference/63966864 45. Malyshkina, A., Brüggemann, A., Paschen, A., Dittmer, U., Cytotoxic CD4+ T cells in chronic viral infections and cancer (2023) Front. Immunol., 14 45 false true Reference 63966865 /api/reference/63966865 46. Liu, D., Gao, S., Zhai, Y., Yang, X., Zhai, G., Research progress of tumor targeted drug delivery based on PD-1/PD-L1 (2022) Int. J. Pharm., 616 46 false true Reference 63966866 /api/reference/63966866 47. Marshall, H.T., Djamgoz, M.B., Immuno-oncology: emerging targets and combination therapies (2018) Front. Oncol., 8, p. 315 47 false true Reference 63966867 /api/reference/63966867 48. Filippone, A., Lanza, M., Mannino, D., Raciti, G., Colarossi, C., Sciacca, D., PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression (2022) Cancer Immunol. Immunother., 71 (9), pp. 2067-2075 48 false true Reference 63966868 /api/reference/63966868 49. Jiang, Y., Chen, M., Nie, H., Yuan, Y., PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations (2019) Hum. Vaccin. Immunother. 49 false true Reference 63966869 /api/reference/63966869 50. Caccese, M., Indraccolo, S., Zagonel, V., Lombardi, G., PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: a concise review (2019) Crit. Rev. Oncol. Hematol., 135, pp. 128-134 50 false true Reference 63966870 /api/reference/63966870 51. Grosso, J.F., Jure-Kunkel, M.N., CTLA-4 blockade in tumor models: an overview of preclinical and translational research (2013) Cancer Immun., 13 (1) 51 false true Reference 63966871 /api/reference/63966871 52. Ahmed, M., Modulation of the Tumor Microenvironment To Overcome Glioblastoma Treatment Resistance (2021), Université Paris-Saclay 52 false true Reference 63966872 /api/reference/63966872 53. Shu, C., Li, Q., Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma (2020) Crit. Rev. Oncol. Hematol., 151 53 false true Reference 63966873 /api/reference/63966873 54. Khasraw, M., Reardon, D.A., Weller, M., Sampson, J.H., PD-1 inhibitors: do they have a future in the treatment of glioblastoma? (2020) Clin. Cancer Res., 26 (20), pp. 5287-5296 54 false true Reference 63966874 /api/reference/63966874 55. Mandal, C.C., Mehta, J., Prajapati, V.K., Programmed Death 1 (PD 1)‐Mediated T‐Cell Apoptosis and Cancer Immunotherapy (2018), pp. 695-722. , The Many Ways Cells Die Apoptosis and Beyond 55 false true Reference 63966875 /api/reference/63966875 56. Harary, M., Reardon, D.A., Iorgulescu, J.B., Efficacy and safety of immune checkpoint blockade for brain metastases (2019) Taylor & Francis, , p. CNS33 56 false true Reference 63966876 /api/reference/63966876 57. Marjańska, A., Drogosiewicz, M., Dembowska-Bagińska, B., Pawińska-Wąsikowska, K., Balwierz, W., Bobeff, K., Nivolumab for the treatment of advanced pediatric malignancies (2020) Anticancer Res, 40 (12), pp. 7095-7100 57 false true Reference 63966877 /api/reference/63966877 58. Migali, C., (2023), Site-and histology-independent indications of medicinal products in oncology 58 false true Reference 63966878 /api/reference/63966878 59. DiDomenico, J., Lamano, J.B., Oyon, D., Li, Y., Veliceasa, D., Kaur, G., The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma (2018) Oncoimmunology., 7 (7) 59 false true Reference 63966879 /api/reference/63966879 60. Luksik, A.S., Maxwell, R., Garzon-Muvdi, T., Lim, M., The role of immune checkpoint inhibition in the treatment of brain tumors (2017) Neurotherapeutics, 14 (4), pp. 1049-1065 60 false true Reference 63966880 /api/reference/63966880 61. Eguren-Santamaria, I., Sanmamed, M.F., Goldberg, S.B., Kluger, H.M., Idoate, M.A., Lu, B.Y., PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice (2020) Clin. Cancer Res., 26 (16), pp. 4186-4197 61 false true Reference 63966881 /api/reference/63966881 62. Yu, M.W., Quail, D.F., Immunotherapy for glioblastoma: current progress and challenges (2021) Front. Immunol., 12 62 false true Reference 63966882 /api/reference/63966882 63. Habashy, K.J., Mansour, R., Moussalem, C., Sawaya, R., Massaad, M.J., Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them (2022) Br. J. Cancer, 127 (6), pp. 976-987 63 false true Reference 63966883 /api/reference/63966883 64. Gras Navarro, A., Björklund, A.T., Chekenya, M., Therapeutic potential and challenges of natural killer cells in treatment of solid tumors (2015) Front. Immunol., 6, p. 202 64 false true Reference 63966884 /api/reference/63966884 65. Chen, H., Li, M., Guo, Y., Zhong, Y., He, Z., Xu, Y., Immune response in glioma's microenvironment (2021) Innovat. Sur. Sci., 5 (3-4), pp. 115-125 65 false true Reference 63966885 /api/reference/63966885 66. Litak, J., Mazurek, M., Grochowski, C., Kamieniak, P., Roliński, J., PD-L1/PD-1 axis in glioblastoma multiforme (2019) Int. J. Mol. Sci., 20 (21), p. 5347 66 false true Reference 63966886 /api/reference/63966886 67. Arrieta, V.A., Dmello, C., McGrail, D.J., Brat, D.J., Lee-Chang, C., Heimberger, A.B., Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment (2023) J. Clin. Invest., 133 (2) 67 false true Reference 63966887 /api/reference/63966887 68. Garcia-Fabiani, M.B., Haase, S., Comba, A., Carney, S., McClellan, B., Banerjee, K., Genetic alterations in gliomas remodel the tumor immune microenvironment and impact immune-mediated therapies (2021) Front. Oncol., 11 68 false true Reference 63966888 /api/reference/63966888 69. Genoud, V., Migliorini, D., Challenging hurdles of current targeting in glioblastoma: a focus on immunotherapeutic strategies (2021) Int. J. Mol. Sci., 22 (7), p. 3493 69 false true Reference 63966889 /api/reference/63966889 70. Shergold, A.L., Millar, R., Nibbs, R.J., Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade (2019) Pharmacol. Res., 145 70 false true Reference 63966890 /api/reference/63966890 71. Mejía-Guarnizo, L.V., Monroy-Camacho, P.S., Turizo-Smith, A.D., Rodríguez-García, J.A., The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy (2023) Front. Immunol., 14 71 false true Reference 63966891 /api/reference/63966891 72. Fei, X., Wu, J., Tian, H., Jiang, D., Chen, H., Yan, K., Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements. Cancer Biomarkers. 2024(Preprint):1-24 72 false true Reference 63966892 /api/reference/63966892 73. Sanders, S., Debinski, W., Challenges to successful implementation of the immune checkpoint inhibitors for treatment of glioblastoma (2020) Int. J. Mol. Sci., 21 (8), p. 2759 73 false true Reference 63966893 /api/reference/63966893 74. Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Immune-related adverse events of immune checkpoint inhibitors: a review (2023) Front. Immunol., 14 74 false true Reference 63966894 /api/reference/63966894 75. Naimi, A., Mohammed, R.N., Raji, A., Chupradit, S., Yumashev, A.V., Suksatan, W., Tumor immunotherapies by immune checkpoint inhibitors (ICIs) 75 false true Reference 63966895 /api/reference/63966895 76. the pros and cons (2022) Cell Commun. Signaling, 20 (1), p. 44 76 false true Reference 63966896 /api/reference/63966896 77. Wojtukiewicz, M.Z., Rek, M.M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A.M., Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners (2021) Cancer Metastasis Rev., 40, pp. 949-982 77 false true Reference 63966897 /api/reference/63966897 78. Chruściel, E., Urban-Wójciuk, Z., Arcimowicz, Ł., Kurkowiak, M., Kowalski, J., Gliwiński, M., Adoptive cell therapy—harnessing antigen-specific T cells to target solid tumours (2020) Cancers, 12 (3), p. 683 78 false true Reference 63966898 /api/reference/63966898 79. Qin, S.S., Melucci, A.D., Chacon, A.C., Prieto, P.A., Adoptive T cell therapy for solid tumors: pathway to personalized standard of care (2021) Cells., 10 (4), p. 808 79 false true Reference 63966899 /api/reference/63966899 80. Chen, Y.H., Kovács, T., Ferdinandy, P., Varga, Z.V., Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors (2024) Br. J. Pharmacol. 80 false true Reference 63966900 /api/reference/63966900 81. Saxena, M., van der Burg, S.H., Melief, C.J., Bhardwaj, N., Therapeutic cancer vaccines (2021) Nat. Rev. Cancer, 21 (6), pp. 360-378 81 false true Reference 63966901 /api/reference/63966901 82. Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., Dong, C., Therapeutic cancer vaccines: advancements, challenges, and prospects (2023) Signal Transduct. Target. Ther., 8 (1), p. 450 82 false true Reference 63966902 /api/reference/63966902 83. Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., Targeting cytokine and chemokine signaling pathways for cancer therapy (2024) Signal Transduct. Target. Ther., 9 (1), p. 176 83 false true Reference 63966903 /api/reference/63966903 84. Pires, I.S., Hammond, P.T., Irvine, D.J., Engineering strategies for immunomodulatory cytokine therapies: challenges and clinical progress (2021) Advanced Therapeutics., 4 (8) 84 false true Reference 63966904 /api/reference/63966904 85. Tian, Y., Xie, D., Yang, L., Engineering strategies to enhance oncolytic viruses in cancer immunotherapy (2022) Signal Transduct. Target. Ther., 7 (1), p. 117 85 false true Reference 63966905 /api/reference/63966905 86. Keshavarz, M., Miri, S.M., Behboudi, E., Arjeini, Y., Dianat-Moghadam, H., Ghaemi, A., Oncolytic virus delivery modulated immune responses toward cancer therapy: challenges and perspectives (2022) Int. Immunopharmacol., 108 86 false true Reference 63966906 /api/reference/63966906 87. Dutta, J., Engineering of polysaccharides via nanotechnology (2013), pp. 87-134. , Biomedicine and Nanotechnology Multifaceted Development and Application of Biopolymers for Biology 87 false true Reference 63966907 /api/reference/63966907 88. Ferraris, C., Cavalli, R., Panciani, P.P., Battaglia, L., Overcoming the blood–brain barrier: successes and challenges in developing nanoparticle-mediated drug delivery systems for the treatment of brain tumours (2020) Int. J. Nanomed., 2999-3022 88 false true Reference 63966908 /api/reference/63966908 89. Mulvihill, J.J., Cunnane, E.M., Ross, A.M., Duskey, J.T., Tosi, G., Grabrucker, A.M., Drug delivery across the blood–brain barrier: recent advances in the use of nanocarriers (2020) Nanomedicine, 15 (2), pp. 205-214 89 false true Reference 63966909 /api/reference/63966909 90. Teleanu, R.I., Preda, M.D., Niculescu, A.-G., Vladâcenco, O., Radu, C.I., Grumezescu, A.M., Current strategies to enhance delivery of drugs across the blood–brain barrier (2022) Pharmaceutics., 14 (5), p. 987 90 false true Reference 63966910 /api/reference/63966910 91. Naderinezhad, S., Amoabediny, G., Haghiralsadat, F., Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers (2017) RSC Adv., 7 (48), pp. 30008-30019 91 false true Reference 63966911 /api/reference/63966911 92. Allahou, L.W., Madani, S.Y., Seifalian, A., Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer (2021) Int. J. Biomat., 2021 (1) 92 false true Reference 63966912 /api/reference/63966912 93. Mojarad-Jabali, S., Farshbaf, M., Walker, P.R., Hemmati, S., Fatahi, Y., Zakeri-Milani, P., An update on actively targeted liposomes in advanced drug delivery to glioma (2021) Int. J. Pharm., 602 93 false true Reference 63966913 /api/reference/63966913 94. Sherje, A.P., Jadhav, M., Dravyakar, B.R., Kadam, D., Dendrimers: a versatile nanocarrier for drug delivery and targeting (2018) Int. J. Pharm., 548 (1), pp. 707-720 94 false true Reference 63966914 /api/reference/63966914 95. Choudhury, H., Pandey, M., Mohgan, R., Jong, J.S.J., David, R.N., Ngan, W.Y., Dendrimer-based delivery of macromolecules for the treatment of brain tumor (2022) Biomater. Adv., 141 95 false true Reference 63966915 /api/reference/63966915 96. Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J.F.W., Hennink, W.E., Polymeric micelles in anticancer therapy: targeting, imaging and triggered release (2010) Pharm. Res., 27, pp. 2569-2589 96 false true Reference 63966916 /api/reference/63966916 97. Liu, Y., Lu, W., Recent advances in brain tumor-targeted nano-drug delivery systems (2012) Expert Opin. Drug Deliv., 9 (6), pp. 671-686 97 false true Reference 63966917 /api/reference/63966917 98. Gothwal, A., Khan, I., Gupta, U., Polymeric micelles: recent advancements in the delivery of anticancer drugs (2016) Pharm. Res., 33, pp. 18-39 98 false true Reference 63966918 /api/reference/63966918 99. Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., Couvreur, P., Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery (2013) Chem. Soc. Rev., 42 (3), pp. 1147-1235 99 false true Reference 63966919 /api/reference/63966919 100. Acharya, S., Sahoo, S.K., PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect (2011) Adv. Drug Deliv. Rev., 63 (3), pp. 170-183 100 false true Reference 63966920 /api/reference/63966920 101. He, C., Hu, Y., Yin, L., Tang, C., Yin, C., Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles (2010) Biomaterials, 31 (13), pp. 3657-3666 101 false true Reference 63966921 /api/reference/63966921 102. Gopinath, P., (2015), Cancer nanotheranostics: Springer 102 false true Reference 63966922 /api/reference/63966922 103. . Uday Kumar S, Matai I, Bhushan B, Malwal D, Sachdev A 103 false true Reference 63966923 /api/reference/63966923 104. Makadia, H.K., Siegel, S.J., Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier (2011) Polymers, 3 (3), pp. 1377-1397 104 false true Reference 63966924 /api/reference/63966924 105. Adamo, G., Campora, S., Ghersi, G., Functionalization of nanoparticles in specific targeting and mechanism release (2017), pp. 57-80. , Elsevier Nanostructures for novel therapy 105 false true Reference 63966925 /api/reference/63966925 106. Kang, C., Sun, Y., Zhu, J., Li, W., Zhang, A., Kuang, T., Delivery of nanoparticles for treatment of brain tumor (2016) Curr. Drug Metab., 17 (8), pp. 745-754 106 false true Reference 63966926 /api/reference/63966926 107. Choudhury, H., Pandey, M., Chin, P.X., Phang, Y.L., Cheah, J.Y., Ooi, S.C., Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends (2018) Drug Deliv. Transl. Res., 8, pp. 1545-1563 107 false true Reference 63966927 /api/reference/63966927 108. Mendes, M., Sousa, J.J., Pais, A., Vitorino, C., Targeted theranostic nanoparticles for brain tumor treatment (2018) Pharmaceutics., 10 (4), p. 181 108 false true Reference 63966928 /api/reference/63966928 109. Westphal, M., Maire, C.L., Lamszus, K., EGFR as a target for glioblastoma treatment: an unfulfilled promise (2017) CNS Drugs, 31, pp. 723-735 109 false true Reference 63966929 /api/reference/63966929 110. Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., Chen, X., Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics (2019) Chem. Soc. Rev., 48 (11), pp. 2967-3014 110 false true Reference 63966930 /api/reference/63966930 111. Fam, S.Y., Chee, C.F., Yong, C.Y., Ho, K.L., Mariatulqabtiah, A.R., Tan, W.S., Stealth coating of nanoparticles in drug-delivery systems (2020) Nanomaterials, 10 (4), p. 787 111 false true Reference 63966931 /api/reference/63966931 112. Malekpour, M.R., Hosseindoost, S., Madani, F., Kamali, M., Adabi, M., Combination nanochemotherapy of brain tumor using polymeric nanoparticles loaded with doxorubicin and paclitaxel: an in vitro and in vivo study (2023) Eur. J. Pharm. Biopharm., 193, pp. 175-186 112 false true Reference 63966932 /api/reference/63966932 113. Qiu, J., Kong, L., Cao, X., Li, A., Wei, P., Wang, L., Enhanced delivery of therapeutic siRNA into glioblastoma cells using dendrimer-entrapped gold nanoparticles conjugated with β-cyclodextrin (2018) Nanomaterials, 8 (3), p. 131 113 false true Reference 63966933 /api/reference/63966933 114. Arzani, H., Adabi, M., Mosafer, J., Dorkoosh, F., Khosravani, M., Maleki, H., Preparation of curcumin-loaded PLGA nanoparticles and investigation of its cytotoxicity effects on human glioblastoma U87MG cells (2019) Biointerface Res. Appl. Chem., 9 (5), pp. 4225-4231 114 false true Reference 63966934 /api/reference/63966934 115. Erthal, L.C., Gobbo, O.L., Ruiz-Hernandez, E., Biocompatible copolymer formulations to treat glioblastoma multiforme (2021) Acta Biomater., 121, pp. 89-102 115 false true Reference 63966935 /api/reference/63966935 116. Kim, S.-S., Rait, A., Kim, E., DeMarco, J., Pirollo, K.F., Chang, E.H., Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma (2015) Cancer Lett., 369 (1), pp. 250-258 116 false true Reference 63966936 /api/reference/63966936 117. Norouzi, M., Yathindranath, V., Thliveris, J.A., Kopec, B.M., Siahaan, T.J., Miller, D.W., Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles (2020) Sci. Rep., 10 (1), p. 11292 117 false true Reference 63966937 /api/reference/63966937 118. Xie, J., Tan, R.S., Wang, C.H., Biodegradable microparticles and fiber fabrics for sustained delivery of cisplatin to treat C6 glioma in vitro. Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials. 2008 118 false true Reference 63966939 /api/reference/63966939 119. Nan, J., Yang, W., Xie, Y., Yu, M., Chen, Y., Zhang, J., Emerging nano‐immunotherapeutic approaches to glioma (2023) Small Struct., 4 (8) 119 false true Reference 63966940 /api/reference/63966940 120. Marei, H.E., Multimodal targeting of glioma with functionalized nanoparticles (2022) Cancer Cell Int., 22 (1), p. 265 120 false true Reference 63966941 /api/reference/63966941 121. Ruan, S., Xie, R., Qin, L., Yu, M., Xiao, W., Hu, C., Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment (2019) Nano Lett., 19 (11), pp. 8318-8332 121 false true Reference 63966942 /api/reference/63966942 122. Thierry, B., Drug nanocarriers and functional nanoparticles: applications in cancer therapy (2009) Curr. Drug Deliv., 6 (4), pp. 391-403 122 false true Reference 63966943 /api/reference/63966943 123. Guido, C., Baldari, C., Maiorano, G., Mastronuzzi, A., Carai, A., Quintarelli, C., Nanoparticles for diagnosis and target therapy in pediatric brain cancers (2022) Diagnostics., 12 (1), p. 173 123 false true Reference 63966944 /api/reference/63966944 124. Nehra, M., Uthappa, U., Kumar, V., Kumar, R., Dixit, C., Dilbaghi, N., Nanobiotechnology-assisted therapies to manage brain cancer in personalized manner (2021) J. Control. Release, 338, pp. 224-243 124 false true Reference 63966945 /api/reference/63966945 125. Ramalho, M.J., Loureiro, J.A., Coelho, M.A., Pereira, M.C., Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma (2022) Pharmaceutics., 14 (2), p. 279 125 false true Reference 63966946 /api/reference/63966946 126. R Nogueira-Librelotto D, F Codevilla C, Farooqi A, MB Rolim C. Transferrin-conjugated nanocarriers as active-targeted drug delivery platforms for cancer therapy. Current pharmaceutical design. 2017 126 false true Reference 63966947 /api/reference/63966947 127. 23(3):454-66 127 false true Reference 63966948 /api/reference/63966948 128. Tashima, T., Smart strategies for therapeutic agent delivery into brain across the blood–brain barrier using receptor-mediated transcytosis (2020) Chem. Pharm. Bull., 68 (4), pp. 316-325 128 false true Reference 63966949 /api/reference/63966949 129. Khaddour, K., Johanns, T.M., Ansstas, G., The landscape of novel therapeutics and challenges in glioblastoma multiforme: contemporary state and future directions (2020) Pharmaceuticals., 13 (11), p. 389 129 false true Reference 63966950 /api/reference/63966950 130. Bai, F., Deng, Y., Li, L., Lv, M., Razzokov, J., Xu, Q., (2024), editors. Advancements and challenges in brain cancer therapeutics. Exploration Wiley Online Library 130 false true Reference 63966951 /api/reference/63966951 131. Kudruk, S., Forsyth, C.M., Dion, M.Z., Hedlund Orbeck, J.K., Luo, J., Klein, R.S., Multimodal neuro-nanotechnology: challenging the existing paradigm in glioblastoma therapy (2024) Proceedings of the National Academy of Sciences 131 false true Reference 63966952 /api/reference/63966952 132. Annu, S.A., Qamar, Z., Md, S., Alhakamy, N.A., Baboota, S., An insight to brain targeting utilizing polymeric nanoparticles: effective treatment modalities for neurological disorders and brain tumor. Front Bioeng (2022) Biotechnol., 10 132 false true Reference 63966953 /api/reference/63966953 133. Iscaro, A., Howard, N.F., Muthana, M., Nanoparticles: properties and applications in cancer immunotherapy (2019) Curr. Pharm. Des., 25 (17), pp. 1962-1979 133 false true Reference 63966954 /api/reference/63966954 134. Som, A., Rosenboom, J.-G., Chandler, A., Sheth, R.A., Wehrenberg-Klee, E., Image-guided intratumoral immunotherapy: developing a clinically practical technology (2022) Adv. Drug Deliv. Rev., 189 134 false true Reference 63966955 /api/reference/63966955 135. Zhao, C., Zhu, X., Tan, J., Mei, C., Cai, X., Kong, F., Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment (2024) Biomed. Pharmacother., 171 135 false true Reference 63966956 /api/reference/63966956 136. Taiarol, L., (2023), Design and validation of lipidic carriers for drug delivery in brain cancer therapy 136 false true Reference 63966957 /api/reference/63966957 137. Mao, W., Yoo, H.S., Inorganic nanoparticle functionalization strategies in immunotherapeutic applications (2024) Biomater. Res. 137 false true Reference 63966958 /api/reference/63966958 138. Huang, H., Liu, R., Yang, J., Dai, J., Fan, S., Pi, J., Gold nanoparticles: construction for drug delivery and application in cancer immunotherapy (2023) Pharmaceutics., 15 (7), p. 1868 138 false true Reference 63966959 /api/reference/63966959 139. Sheervalilou, R., Shirvaliloo, M., Sargazi, S., Ghaznavi, H., Recent advances in iron oxide nanoparticles for brain cancer theranostics: from in vitro to clinical applications (2021) Expert Opin. Drug Deliv., 18 (7), pp. 949-977 139 false true Reference 63966960 /api/reference/63966960 140. Wang, T., Suita, Y., Miriyala, S., Dean, J., Tapinos, N., Shen, J., Advances in lipid-based nanoparticles for cancer chemoimmunotherapy (2021) Pharmaceutics., 13 (4), p. 520 140 false true Reference 63966961 /api/reference/63966961 141. Manna, S., Mahata, R., Dey, S.K., Das Chaudhuri, A., Choudhury, S.M., Multifunctional aptamer grafted targeted nano‐drugs execute molecular cross‐talks with cancer cells (2024) Appl. Res., 3 (4) 141 false true Reference 63966962 /api/reference/63966962 142. Rehan, F., Zhang, M., Fang, J., Greish, K., Therapeutic applications of nanomedicine: recent developments and future perspectives (2024) Molecules, 29 (9), p. 2073 142 false true Reference 63966963 /api/reference/63966963 143. Upton, D.H., Ung, C., George, S.M., Tsoli, M., Kavallaris, M., Ziegler, D.S., Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy (2022) Theranostics., 12 (10), p. 4734 143 false true Reference 63966964 /api/reference/63966964 144. Schulz, M., Salamero-Boix, A., Niesel, K., Alekseeva, T., Sevenich, L., Microenvironmental regulation of tumor progression and therapeutic response in brain metastasis (2019) Front. Immunol., 10, p. 1713 144 false true Reference 63966965 /api/reference/63966965 145. Charles, N.A., Holland, E.C., Gilbertson, R., Glass, R., Kettenmann, H., The brain tumor microenvironment (2012) Glia, 60 (3), pp. 502-514 145 false true Reference 63966966 /api/reference/63966966 146. Chen, W., Tang, C., Chen, G., Li, J., Li, N., Zhang, H., Boosting checkpoint immunotherapy with biomimetic nanodrug delivery systems (2024) Adv. Healthc. Mater., , 2304284 146 false true Reference 63966967 /api/reference/63966967 147. Neophytou, C.M., Pierides, C., Christodoulou, M.-I., Costeas, P., Kyriakou, T.-C., Papageorgis, P., The role of tumor-associated myeloid cells in modulating cancer therapy (2020) Front. Oncol., 10, p. 899 147 false true Reference 63966968 /api/reference/63966968 148. Paranthaman, S., Goravinahalli Shivananjegowda, M., Mahadev, M., Moin, A., Hagalavadi Nanjappa, S., Nanjaiyah, N.D., Nanodelivery systems targeting epidermal growth factor receptors for glioma management (2020) Pharmaceutics., 12 (12), p. 1198 148 false true Reference 63966969 /api/reference/63966969 149. Parakh, S., Nicolazzo, J., Scott, A.M., Gan, H.K., Antibody drug conjugates in glioblastoma–is there a future for them? (2021) Front. Oncol., 11 149 false true Reference 63966970 /api/reference/63966970 150. Singh, D.D., Yadav, D.K., TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy (2021) Biomedicines., 9 (8), p. 876 150 false true Reference 63966971 /api/reference/63966971 151. Ruiz-Molina, D., Mao, X., Alfonso-Triguero, P., Lorenzo, J., Bruna, J., Yuste, V.J., Advances in preclinical/clinical glioblastoma treatment: can nanoparticles be of help? (2022) Cancers, 14 (19), p. 4960 151 false true Reference 63966972 /api/reference/63966972 152. Li, T., Sun, S., Li, Y., Zhang, Y., Wei, L., Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes (2024) Front. Immunol., 15 152 false true Reference 63966973 /api/reference/63966973 153. Park, K., Veena, M.S., Shin, D.S., Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies (2022) Front. Cell Dev. Biol., 10 153 false true Reference 63966974 /api/reference/63966974 154. Wang, X., Guo, G., Guan, H., Yu, Y., Lu, J., Yu, J., Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma (2019) J. Exp. Clin. Cancer Res., 38, pp. 1-13 154 false true Reference 63966975 /api/reference/63966975 155. Keshavarz, A., Pourbagheri-Sigaroodi, A., Zafari, P., Bagheri, N., Ghaffari, S.H., Bashash, D., Toll‐like receptors (TLRs) in cancer 155 false true Reference 63966977 /api/reference/63966977 156. Rahmat, J.N., Liu, J., Chen, T., Li, Z., Zhang, Y., Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation (2024) Chem. Soc. Rev. 156 false true Reference 63966978 /api/reference/63966978 157. Hu, D., Zhang, W., Tang, J., Zhou, Z., Liu, X., Shen, Y., Improving safety of cancer immunotherapy via delivery technology (2021) Biomaterials, 265 157 false true Reference 63966979 /api/reference/63966979 158. Guadagno, E., Presta, I., Maisano, D., Donato, A., Pirrone, C.K., Cardillo, G., Role of macrophages in brain tumor growth and progression (2018) Int. J. Mol. Sci., 19 (4), p. 1005 158 false true Reference 63966980 /api/reference/63966980 159. Akins, E.A., Aghi, M.K., Kumar, S., Incorporating tumor-associated macrophages into engineered models of glioma (2020) Iscience., 23 (12) 159 false true Reference 63966981 /api/reference/63966981 160. Li, K., Yang, D., Liu, D., Targeted nanophotoimmunotherapy potentiates cancer treatment by enhancing tumor immunogenicity and improving the immunosuppressive tumor microenvironment (2023) Bioconjug. Chem., 34 (2), pp. 283-301 160 false true Reference 63966982 /api/reference/63966982 161. Tritz, Z.P., Ayasoufi, K., Johnson, A.J., Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail (2021) Neuro-Oncol. Adv., 31)vdab066 161 false true Reference 63966983 /api/reference/63966983 162. Kiaie, S.H., Salehi-Shadkami, H., Sanaei, M.J., Azizi, M., Shokrollahi Barough, M., Nasr, M.S., Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy (2023) J. Nanobiotechnol., 21 (1), p. 339 162 false true Reference 63966984 /api/reference/63966984 163. Sood, S., Jayachandiran, R., Pandey, S., Current advancements and novel strategies in the treatment of metastatic melanoma. Integrative cancer therapies. 2021 163 false true Reference 63966985 /api/reference/63966985 164. 20:1534735421990078 164 false true Reference 63966986 /api/reference/63966986 165. Jiang, M., Qin, B., Li, X., Liu, Y., Guan, G., You, J., New advances in pharmaceutical strategies for sensitizing anti‐PD‐1 immunotherapy and clinical research (2023) Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 15 (1), p. e1837 165 false true Reference 63966987 /api/reference/63966987 166. Fang, Z., Wan, L.-Y., Chu, L.-Y., Zhang, Y.-Q., Wu, J.-F., ‘Smart'nanoparticles as drug delivery systems for applications in tumor therapy (2015) Expert Opin. Drug Deliv., 12 (12), pp. 1943-1953 166 false true Reference 63966988 /api/reference/63966988 167. Appin, C.L., Brat, D.J., Molecular genetics of gliomas (2014) The Cancer Journal., 20 (1), pp. 66-72 167 false true Reference 63966989 /api/reference/63966989 168. Wang, N., Li, X., Xiao, J., Liu, S., Cao, D., Data-driven toxicity prediction in drug discovery: current status and future directions (2024) Drug Discov. Today, , 104195 168 false true Reference 63966990 /api/reference/63966990 169. Dong, S., Ma, Z., Combination of JAK inhibitor and immune checkpoint inhibitor in clinical trials: a breakthrough (2024) Front. Immunol., 15 169 false true Reference 63966991 /api/reference/63966991 170. Han, R., Rao, X., Zhou, H., Lu, L., Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy (2024) Int. J. Nanomed., 4803-34 170 false true Reference 63966992 /api/reference/63966992 171. Khot, S., Krishnaveni, A., Gharat, S., Momin, M., Bhavsar, C., Omri, A., Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment. Expert Opinion on Drug Delivery. 2024(just-accepted) 171 false true Reference 63966993 /api/reference/63966993 172. Hsieh, H.-T., Huang, H.-C., Chung, C.-W., Chiang, C.-C., Hsia, T., Wu, H.-F., CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma (2022) J. Control. Release, 352, pp. 920-930 172 false true Reference 63966994 /api/reference/63966994 173. Zhang, L., Liu, Y., Huang, H., Xie, H., Zhang, B., Xia, W., Multifunctional nanotheranostics for near infrared optical imaging-guided treatment of brain tumors (2022) Adv. Drug Deliv. Rev., 190 173 false true Reference 63966995 /api/reference/63966995 174. Bezelya, A., Küçüktürkmen, B., Bozkır, A., (2023), editors. Microfluidic Devices for Precision Nanoparticle Production. Micro MDPI 174 false true Reference 63966996 /api/reference/63966996 175. Halamoda-Kenzaoui, B., Vandebriel, R., Howarth, A., Siccardi, M., David, C., Liptrott, N., Methodological needs in the quality and safety characterisation of nanotechnology-based health products: priorities for method development and standardisation (2021) J. Control. Release, 336, pp. 192-206 175 false true Reference 63966997 /api/reference/63966997 176. Bhattacharya, R., Bose, D., Kaur, T., Patel, R., Renuka, O., Rodriguez, R.V., Model organoids: integrated frameworks for the next frontier of healthcare advancements (2024) Stem Cell Rev. Rep., pp. 1-18 176 false true Reference 63966998 /api/reference/63966998 177. Rae, C., Amato, F., Braconi, C., Patient-derived organoids as a model for cancer drug discovery (2021) Int. J. Mol. Sci., 22 (7), p. 3483 177 false true Reference 63966999 /api/reference/63966999 178. Pamarthy, S., Sabaawy, H.E., Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine (2021) Mol. Cancer, 20 (1), p. 125 178 false true Reference 63967000 /api/reference/63967000 179. Rahman, R., Polley, M.-Y.-C., Alder, L., Brastianos, P.K., Anders, C.K., Tawbi, H.A., Conference, N.-O., Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for (2023) Lancet Oncol., 24 (4), pp. e161-e171 179 false true /api/publication/35780405 Liu J. et al. Nanoengineered immune check point inhibitors delivery for targeted brain cancer treatment: Current status and future perspectives. (2025) BIOCHEMICAL PHARMACOLOGY 0006-2952 1873-2968 233<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Liu J. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Wang Y. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Song Z. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Zhang Y. </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35780405" target="_blank">Nanoengineered immune check point inhibitors delivery for targeted brain cancer treatment: Current status and future perspectives</a></div> <div> <span class="journal-title">BIOCHEMICAL PHARMACOLOGY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0006-2952">0006-2952</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1873-2968">1873-2968</a>)</span>: <span class="journal-volume">233</span> <span class="page"> Paper 116789. 15 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1016/j.bcp.2025.116789" target="_blank" href="https://doi.org/10.1016/j.bcp.2025.116789"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001424517500001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001424517500001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:black" title="85216918520" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85216918520"> Scopus </a> </span> </span> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35780405&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 1 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 35780405</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">Scopus</span> </div> <div class="lastModified">Utolsó módosítás: 2025.03.20. 06:52 Szuper Admin (admin) </div> </div></div>